Background: Human herpesvirus 6 (HHV-6) encephalitis/myelitis is now a well-known
| PATIENTS AND METHODS

| Patients
Between 2007 and 2015, 253 adult patients underwent allo-HSCT in our institute and medical records of these patients were reviewed.
This study was approved by our Institutional Review Board and was conducted according to the guidelines of the Declaration of Helsinki.
| Conditioning regimen
Myeloablative conditioning (MAC) regimens were defined as using total body irradiation (TBI) with fractionated doses of >8 Gy, busulfan
T A B L E 1 Patient characteristics
Characteristics Total
HHV-6 encephalitis/myelitis
P-value Yes (n=13)
No (n=240) 
| Graft-versus-host disease (GVHD) prophylaxis
GVHD prophylactic regimens include tacrolimus (TAC), cyclosporine (CsA), methotrexate (MTX), mycophenolate mofetil (MMF), antithymocyte globulin (ATG), and post-transplantation cyclophosphamide (PTCY). CsA was given aiming for therapeutic trough levels between 150 and 300 ng/mL in divided dose q12h or between 250
and 400 ng/mL in continuous infusion. TAC was given aiming for therapeutic levels between 10 and 15 ng/mL in continuous infusion. MMF was administered at a dose of 30 mg/kg/day and MTX was administered at a dose of 15 or 10 mg/m 2 on day 1, and 10 or 7 mg/m 2 on day 3 and 6 after transplantation. PTCY was used in the setting of allo-HSCT from human leukocyte antigen (HLA) haploidentical donor. 
| HHV-6 encephalitis/myelitis
HHV-6 encephalitis was defined as presence of short-term memory dysfunction, disturbance of consciousness, or seizure in a patient with HHV-6 DNA detected in the cerebrospinal fluid (CSF) (or serum if CSF was unavailable) after exclusion of other causes. HHV-6 myelitis was defined as presence of dysesthesia, lancinating pain, and pruritus of extremities and trunk, or dysautonomia such as bladder and rectal disturbance or tachycardia with HHV-6 DNA detected in the CSF (or serum if CSF was unavailable) after exclusion of other causes. These criteria were based on the previous report and all cases that we studied met this definition. 
| RESULTS
| Patients' characteristics
Patients' characteristics are listed in leukemia (AML, n=77), acute lymphoblastic leukemia (ALL, n=45), chronic myelogenous leukemia (CML, n=8), myelodysplastic syndrome (MDS, n=35), malignant lymphoma (ML, n=56), multiple myeloma (MM, n=6), adult T-cell leukemia/lymphoma (ATLL, n=12), aplastic anemia (AA, n=9), and others (n=5).
Clinical features of patients with HHV-6 encephalitis/myelitis are shown in Table 2 . There were two patients with HHV-6 myelitis characterized by generalized pruritus, discomfort, and pain resembling calcineurin inhibitor-induced pain syndrome. 27 All of the nine patients with HHV-6 encephalitis showed impaired consciousness and disorientation. Two of the nine patients also exhibited pruri- 
| Risk factors
A total of 11 (4.5%) of 253 patients developed HHV-6 encephalitis/myelitis, including 9 (3.7%) with encephalitis and 2 (0.8%) with myelitis at 14-55 days (median, 21 days) after allo-HSCT.
The results of univariate analysis are shown in Table 3 . Incidence of HHV-6 encephalitis/myelitis was higher after CBT than after PBSCT or BMT (11.3% vs 2%, P<.001). That was higher in patients with a history of prior allo-HSCT than those without it (Table 3) .
Pt.
No. HSCT, hematopoietic stem cell transplant; GVHD, graft-versus-host disease; ES, engraftment syndrome; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; CMV, cytomegalovirus; M, male; RIC, reduced-intensity conditioning; UCB, umbilical cord blood; TAC, tacrolimus; mPSL, methylprednisolone; DWI, diffusion-weighted MRI imaging; FLAIR, fluid attenuation inversion recovery; GCV, ganciclovir; AML, acute myeloid leukemia; F, female; URBM, unrelated bome marrow; sMTX, short-term methotrexate; ML, malignant lymphoma; MAC, myeloablative conditioning; FCV, foscavir; MMF, mycophenolate mofetil; MDS, myelodysplastic syndrome; CsA, cyclosporine; AML, acute myeloid leukemia; RPBSC, related periphal blood stem cell; PSL, prednisolone; ATG, anti-thymocyte globulin; ALL, acute lymphoblastic leukemia.
Age
T A B L E 3 Proportional hazards modeling of risk of HHV-6 encephalitis/myelitis after allogenic hematopoietic stem cell transplantation (allo-HSCT) 
| Outcome
All patients were treated with ganciclovir (GCV) or foscavir (FCV), which eliminated HHV-6 DNA in the CSF or serum, but memory dysfunctions were not recovered in two patients.
No patient died of HHV-6 encephalitis/myelitis and seven patients died of other causes, including relapse of the diseases in five patients, infection in one patient, and acute GVHD in one patient (Table 2) .
OS rate at 1 year after transplantation in patients with and without HHV-6 encephalitis/myelitis was 40.0% and 71.3%, respectively ( Figure 1 ). Development of HHV-6 encephalitis/myelitis trended to be associated with poor prognosis (P=.052).
| DISCUSSION
CBT is an obvious risk factor for HHV-6 encephalitis/myelitis. 28 We also demonstrated that CBT was a significant risk of HHV-6 encephalitis/myelitis in this study. This may be associated with the absence of primed HHV-6-specific memory T cells and the immunologic immaturity of CBT. 13,29-31 Yoshihara et al. 32 reported that donor lymphocyte infusion was effective in a patient with HHV-6 encephalitis, suggesting a role of HHV-6-specific T cells in preventing HHV-6 reactivation.
We showed a novel finding that MMF was a significant risk factor for HHV-6 encephalitis/myelitis. Mori et al. 16 previously suggested the association of MMF and HHV-6 encephalitis/myelitis although the association was not statistically significant. MMF is rapidly hydrolyzed after absorption to mycophenolic acid, which reversibly inhibits inosine monophosphate dehydrogenase, leading to decreased B-and T-cell proliferation. MMF also leads to immunosuppression through other mechanisms as well, including the induction of apoptosis of activated T cells and the inhibition of adhesion molecule expression and lymphocyte recruitment. 
34,35
Concerning virus reactivation after allo-HSCT, previous studies showed that MMF was significantly associated with the reactivation of CMV or BK polyomavirus.
36-40
A previous report has found that HHV-6 encephalitis/myelitis occurred more frequently in recipients who underwent two or more HSCTs, especially CBTs. 16 Our study also demonstrated that patients who had a history of prior allo-HSCT developed HHV-6 encephalitis/myelitis more frequently than patients who received allo-HSCT for the first time. When this analysis was restricted to a second CBT or more, the incidence of HHV-6 encephalitis/myelitis increased to
36.5% (5 of 14 patients). It was reported that it took a long time to
restore the ability of the immune system, especially CD4 positive T cells, and there was the association of CD4 positive T-cell counts and infection rates, 41, 42 indicating that history of prior allo-HSCT has association with immune depression at second or greater allo-HSCT, leading to development of HHV-6 encephalitis/myelitis.
In this study, ES was also a risk factor of developing HHV-6 encephalitis/myelitis. It was reported that interleukin 6 was elevated proceeding HHV-6 encephalitis/myelitis and inflammatory condition is considered to be associated with development of HHV-6 encephalitis/ myelitis.
43-45
A previous report showed that MRI in 7 days after development of HHV-6 encephalitis cannot always show typical abnormal signal intensity, such as hyperintensities in the bilateral hippocampus,
23
F I G U R E 1 Overall survival of all patients after allogeneic hematopoietic stem cell transplantation using landmark analysis.
Comparison of patients with human herpesvirus-6 (HHV-6) encephalitis/myelitis (n=10) and those without HHV-6 encephalitis/ myelitis (n=228), P=.052. n. HHV-6, human herpesvirus 6 T A B L E 3 (Continued) although another report indicated effectiveness of diffusionweighted MRI imaging in the early period of HHV-6 encephalitis.
46
In our study, MRI that was carried out in 5 days after development of HHV-6 encephalitis/myelitis did not detect any abnormalities in 6
of 11 HHV-6 encephalitis/myelitis patients. MRI itself may not have an influence on decision for early treatment of HHV-6 encephalitis/ myelitis and it may be reasonable to consider MRI as a diagnostic support.
Incidence of HHV-6 encephalitis/myelitis in our study was similar to the results in previous studies. 2, 8, 9, [11] [12] [13] FCV is currently used to treat HHV-6 encephalitis/myelitis, however, the outcome has been reported to still be dismal with inferior survival and significant sequelae. In this study, two patients developed HHV-6 encephalitis/ myelitis during GCV therapy against cytomegalovirus reactivation.
To reduce morbidity and mortality of HHV-6 encephalitis/myelitis, Differentiation of HHV-6 infection and chromosomally integrated HHV-6 is important. 51, 52 We confirmed that HHV-6 viral loads in all patients declined after treatment. Therefore, we could rule out the possibility of chromosomal integration and we consider all patients were definitely diagnosed with HHV-6 encephalitis/myelitis.
This study has some limitations. The first limitation is the small number of cases studied. However, considering predisposition of HHV-6 encephalitis/myelitis after allo-HSCT and the previous reports in which 23 cases were at most reported (median, 9 cases), 2, [8] [9] [10] [11] [12] [13] 25 the number of cases (n=11) studied does not seem to be too small. Secondly, we did not differentiate HHV-6A from HHV-6B in this study, although HHV-6 encephalitis/myelitis after allo-HSCT is considered to be associated with reactivation of HHV-6B in most cases. 53,54 Prospective studies under standardized conditions are needed to better understand physiopathology of HHV-6 encephalitis/myelitis and to establish optimum prophylaxis and treatment.
| CONCLUSION
In summary, HHV-6 encephalitis is not a rare complication of allo-HSCT especially in the setting of CBT, MMF use for GVHD prophylaxis, prior allo-HSCT, and ES. Optimum prophylaxis and preemptive therapy against HHV-6 encephalitis/myelitis have remained elusive.
At the present moment, the understanding of risk factors of HHV-6 encephalitis/myelitis is important for its early diagnosis and treatment. We believe that our identification of a new possible risk factor, MMF, is useful for medical examination and treatment of HHV-6 encephalitis/myelitis, although further prospective studies validating our findings are mandatory.
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